Evidence receipt
OASIS 4: what the trial found
A plain-language summary of one study: who took part, what they got, what it was compared with, what happened in each group, its limits and who paid for it. One trial. Results are group averages, not a prediction for any one person.
Study: OASIS 4[1]
Does daily oral semaglutide 25 mg — the approved Wegovy pill dose — cause weight loss compared with placebo?
- Who was in it
- 307 adults without diabetes, BMI 30 or more, or 27 or more with an obesity-related complication
- What they got
- Oral semaglutide 25 mg once a day, with lifestyle intervention
- Compared with
- Placebo, with lifestyle intervention
- How long
- 64 weeks to the main results
- What happened
- Average weight change: −13.6% vs −2.2% on placebo. Stomach-related side effects: 74.0% vs 42.2%.
- Limits
- Small (307 people)
- People with diabetes were excluded
- No heart-outcome results of its own
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Sources
- Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). New England Journal of Medicine, September 18, 2025. https://pubmed.ncbi.nlm.nih.gov/40934115/ · DOI 10.1056/NEJMoa2500969 · PMID 40934115. Accessed November 2, 2026. Back to the text
Discussed in: Wegovy, explained · Oral semaglutide (Rybelsus, Wegovy pill), explained
General information, not medical advice.